Drug Trial Radar · NCT06827457
A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci120 in Healthy Adults.
Last checked: Nov 20, 2026Latest source record: Dec 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
58
Actual
Start
Feb 20, 2025
Primary completion
Nov 27, 2025
Study completion Dec 16, 2025
Sponsor
- Lead sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is designed to evaluate the safety, tolerability, PK and PD of GenSci120 in a randomized, double-blind, placebo-controlled trial involving healthy adult participants.
Conditions
- Autoimmune Disease
Interventions
GenSci120Drug
Administered SC.
PlaceboDrug
Administered SC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of treatment-emergent adverse events (TEAEs)Time frame: 113 days
- Incidence and severity of serious adverse events (SAEs)Time frame: 113 days
- Clinically significant changes from baselineTime frame: 113 days
- Concentration of GenSci120 in plasma samples.Time frame: 113 days
- Pharmacokinetics-AUC0-lastTime frame: 113 days
- Pharmacokinetics-AUC0-infTime frame: 113 days
- Pharmacokinetics-TmaxTime frame: 113 days
- Pharmacokinetics-CmaxTime frame: 113 days
- Pharmacokinetics-CL/FTime frame: 113 days
- Pharmacokinetics-t1/2Time frame: 113 days
- flow cytometryTime frame: 113 days
- Incidence and the time of anti-drug antibody (ADA) positive and neutralizing antibody (NAb) positive (if applicable) after GenSci120 administration.Time frame: 113 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.